aTYR PHARMA INC

aTyr Pharma, Inc. has filed an amendment to its Certificate of Incorporation to implement a 1-for-40 reverse stock split, effective October 28, 2026. This action will reduce the number of outstanding common shares from approximately 100.5 million to 2.5 million. The reverse split will proportionately adjust all outstanding equity awards and warrants. Fractional shares will be rounded up. Trading on a split-adjusted basis is expected to commence on October 29, 2026, under the same ticker symbol 'ATYR'.

aTyr Pharma reported a consolidated net loss of $10.3 million, or $(0.11) per share, for Q2 2026, a significant improvement from the prior year. Research and development expenses decreased to $6.7 million. The company also announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., effective July 30, 2026, with all rights for efzofitimod in Japan reverting to aTyr Pharma. The company believes its $58.9 million in cash and investments will fund operations for at least one year.

aTyr Pharma announced a significant corporate restructuring, including an approximately 60% workforce reduction and program prioritization, to focus resources on its efzofitimod program in interstitial lung disease (ILD). This move is expected to reduce annualized operating expenses by about $13 million and extend the company's cash runway into late 2028. The company also reported its second quarter 2026 financial results, ending the period with $58.9 million in cash and investments and a consolidated net loss of $10.31 million.

aTyr Pharma announced a corporate restructuring, including a workforce reduction of approximately 60%, to prioritize its efzofitimod program in interstitial lung disease (ILD). This move is expected to reduce annualized operating expenses by $13 million and extend the company's cash runway into late 2028. The company reported $58.9 million in cash and investments at the end of Q2 2026, with a net loss of $10.3 million. Key clinical updates include awaiting FDA comments on its Phase 3 efzofitimod protocol by August 2026 and expecting topline results from the Phase 2 EFZO-CONNECT™ study in Q1 2027.

aTyr Pharma, Inc. announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., effective July 30, 2026. This mutual agreement follows Kyorin's earlier notice of termination without cause. As a result, aTyr Pharma has regained the exclusive rights to develop and commercialize efzofitimod in Japan, and now holds global rights for the product for all forms of interstitial lung disease. The companies also agreed on specific wind-down activities and the termination of other ancillary agreements.

aTyr Pharma announced positive subgroup analysis results from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The 5.0 mg/kg dose demonstrated clinically meaningful benefit in lung function (FVC) and improvements in patient-reported outcomes compared to placebo. Following these results and interactions with the FDA, the company submitted a protocol for a planned Phase 3 study of efzofitimod in this specific patient population, utilizing FVC as the primary endpoint.

aTyr Pharma Inc. has been granted an additional 180-day period by Nasdaq, until November 30, 2026, to regain compliance with the minimum bid price requirement of $1.00 per share. The company had initially received a deficiency notice for failing to meet this requirement. Nasdaq has confirmed that aTyr Pharma meets all other listing standards, and the company intends to cure the deficiency, possibly through a reverse stock split. Failure to comply by the new deadline could lead to the delisting of its common stock from The Nasdaq Capital Market.

aTyr Pharma reported a consolidated net loss of $(10.8) million, or $(0.11) per share, for the first quarter of 2026, an improvement from $(14.9) million, or $(0.17) per share, in the prior year period. This reduction was primarily driven by a significant decrease in research and development expenses. However, the company also announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for efzofitimod in Japan, a partnership that had generated $20.0 million in milestone payments. Additionally, aTyr Pharma is facing ongoing securities class action litigation, with its CFO recently added as a defendant.

aTyr Pharma announced its first quarter 2026 financial results and provided a corporate update, highlighting a clear path forward for efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA. The company plans to submit an IND in June 2026 for a new Phase 3 study for efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis. Additionally, aTyr Pharma is on track to complete enrollment in its Phase 2 EFZO-CONNECT™ study for SSc-ILD in the first half of 2026. The company reported a net loss of $(10.8) million for the quarter, with $68.3 million in cash and investments.

aTyr Pharma announced its participation in two upcoming investor conferences in May and June 2026. The company will attend the RBC Capital Markets Global Healthcare Conference on May 20, 2026, for 1x1 investor meetings. Additionally, aTyr Pharma will participate in the Jefferies Global Healthcare Conference on June 4, 2026, where President and CEO Sanjay S. Shukla will deliver a fireside chat, and management will be available for one-on-one meetings. A webcast of the Jefferies event will be available on the company's website.